Adicet bio appoints julie maltzman, m.d. as chief medical officer

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced the appointment of julie maltzman, m.d. as chief medical officer, effective january 13, 2025. dr. maltzman will lead the adicet clinical development strategy to advance adicet's robust autoimmune and oncology pipeline. “we are incredibly pleased to welcome jul.
ACET Ratings Summary
ACET Quant Ranking